StockNews.com began coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a report issued on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Shares of NYMX opened at $0.38 on Friday. Nymox Pharmaceutical has a fifty-two week low of $0.35 and a fifty-two week high of $2.27. The business has a 50-day moving average of $1.27 and a 200 day moving average of $1.41. The firm has a market cap of $34.31 million, a P/E ratio of -2.11 and a beta of 1.09.
Several institutional investors and hedge funds have recently made changes to their positions in NYMX. Millennium Management LLC boosted its position in shares of Nymox Pharmaceutical by 1,834.9% in the second quarter. Millennium Management LLC now owns 323,364 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 306,652 shares during the period. Citigroup Inc. bought a new position in Nymox Pharmaceutical in the 1st quarter valued at $137,000. Murchinson Ltd. purchased a new position in shares of Nymox Pharmaceutical during the 1st quarter valued at $96,000. WMS Partners LLC bought a new position in shares of Nymox Pharmaceutical in the first quarter worth $53,000. Finally, MAI Capital Management purchased a new stake in shares of Nymox Pharmaceutical in the first quarter worth $44,000. Hedge funds and other institutional investors own 1.09% of the company’s stock.
About Nymox Pharmaceutical (Get Rating)
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.